Efficacy of antifibrinolytic agents on surgical bleeding and transfusion requirements in spine surgery: a meta-analysis.
Spine surgery is usually associated with large amount of blood loss and blood transfusion. Excessive blood loss may cause hypotension, inadequate oxygenation of organs, necessitate allogeneic blood transfusion, and spinal epidural hematoma formation. Aprotinin, TXA, and EACA are antifibrinolytics currently offered as prophylactic agents to reduce surgery-associated blood loss. The purpose of this study was to assess the efficacy of using antifibrinolytic agents in reducing blood loss and blood transfusions in spine surgery.



PubMed, Embase, and Cochrane-controlled trials register were used to identify RCTs published before April 2015 that examined the effectiveness of intravenous aprotinin, tranexamic acid (TXA), and epsilon-aminocaproic acid (EACA) on reduction of blood loss and blood transfusions, compared with placebo in spine surgery. Randomized controlled trials reported the primary outcome that included total blood loss, intra-operative blood loss, post-operative blood loss, blood transfusion requirements, blood transfusion rate, and incidence of deep vein thrombosis. Meta-analysis was performed using the Stata12.0. Weighted mean difference with 95 % confidence intervals was used to summarize the findings across the trials for continuous outcomes. Dichotomous data were expressed as risk ratios with 95 % confidence intervals. A P < 0.05 was considered statistically significant.



17 studies involving 1191 patients were identified. Among them, 13 RCTs with 943 patients were included for the evaluation of total blood loss. Compared with the control group, the antifibrinolytic agents reduced total blood loss (SMD = -0.62; 95 % CI -0.75, -0.48; P = 0.000), The aprotinin group (SMD = -0.80; 95 % CI -1.22, -0.37; P = 0.938), The TXA group (SMD = -0.75; 95 % CI -0.93, -0.57; P = 0.000), and the EACA group (SMD = -0.28; 95 % CI -0.54, -0.01; P = 0.185). Thirteen RCTs with eight hundred and ninety four patients were included for the evaluation of intra-operative blood loss. Compared with the control group, the antifibrinolytic agents reduced intra-operative blood loss (SMD = -0.41; 95 % CI -0.55, -0.28; P = 0.010), The aprotinin group (SMD = -0.62; 95 % CI -0.93, -0.30; P = 0.862), The TXA group (SMD = -0.47; 95 % CI -0.64, -0.29; P = 0.005), and the EACA group (SMD = -0.16; 95 % CI -0.42, -0.11; P = 0.897). Eight RCTs with six hundred and seven patients were included for the evaluation of post-operative blood loss. Compared with the control group, the antifibrinolytic agents reduced post-operative blood loss (SMD = -0.68; 95 % CI -0.85, -0.51; P = 0.000), the aprotinin group (SMD = -0.48; 95 % CI -0.85, -0.12; P = 0.036), the TXA group (SMD = -0.80; 95 % CI -1.01, -0.59; P = 0.000), and the EACA group (SMD = -0.32; 95 % CI -0.68, -0.04; P = 0.009). Ten RCTs with seven hundred and twenty twopatients were included for the evaluation of blood transfusion. Compared with the control group, the antifibrinolytic agents reduced blood transfusion (SMD = -0.68; 95 % CI -0.85, -0.51; P = 0.000), the aprotinin group (SMD = -0.80; 95 % CI -1.22, -0.37; P = 0.938), the TXA group (SMD = -0.38; 95 % CI -0.58, -0.18; P = 0.000), and the EACA group (SMD = -0.28; 95 % CI -0.54, -0.01; P = 0.185). Twelve RCTs with eight hundred and fifteenpatients were included for the evaluation of blood transfusion rate. The transfusion rate was 35.6 % in the patients with antifibrinolytic agents and 55.2 % in the patients with placebo (RR = 0.75; 95 % CI 0.63, 0.89; P = 0.939). All studies were included for the evaluation of safety, with a total of eight thromboembolic events reported overall (two in the experimental group and six in the control group).



The antifibrinolytic agents were able to reduce perioperative blood loss and transfusion requirements in spine surgery. TXA appeared more effective than aprotinin and EACA in reducing total blood loss, intra-operative blood loss, and blood transfusion according to the results of this analysis. The three groups in reducing the post-operative blood loss are significantly better than control groups. There was no evidence that the use of antifibrinolytic agents was a risk factor for thromboembolism in spine surgery. Further multicenter, large-sample, double-blind RCTs are required to confirm the efficacy and safety of the three antifibrinolytic agents in spine surgery.
Graduate School of Tianjin Medical University, Tianjin, 300070, China.
Guang
G
Li
Department of Spinal Surgery, Tian-jin Union Medical Centre, Nankai University People's Hospital, Tianjin, 300121, China. lgluocheng@163.com.
Tian-Wei
TW
Sun
Graduate School of Tianjin Medical University, Tianjin, 300070, China.
Gan
G
Luo
Graduate School of Tianjin Medical University, Tianjin, 300070, China.
Chao
C
Zhang
D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D001803:Blood Transfusion / Q000706:statistics & numerical data*; D006801:Humans; D019106:Postoperative Hemorrhage / Q000517:prevention & control*
D000933:Antifibrinolytic Agents
Antifibrinolytic agents; Blood loss; Blood transfusion; Meta-analysis; Spine surgery
JAMA. 2007 Feb 7;297(5):471-9
17284697
Spine (Phila Pa 1976). 2009 Sep 1;34(19):2096-103
19730217
J Cardiothorac Vasc Anesth. 1999 Jun;13(3):304-8
10392682
Eur Spine J. 2004 Oct;13 Suppl 1:S3-5
15197630
Spine (Phila Pa 1976). 2010 Jan 15;35(2):235-9
20081519
Anesthesiology. 2001 Jul;95(1):64-71; discussion 5A-6A
11465586
Spine (Phila Pa 1976). 2015 Dec;40(24):E1257-63
26208230
Spine (Phila Pa 1976). 1991 Nov;16(11):1277-82
1750000
Circulation. 2007 Jun 5;115(22):2801-13
17533182
Spine (Phila Pa 1976). 2003 Nov 1;28(21):2482-5
14595168
N Engl J Med. 2006 Jan 26;354(4):353-65
16436767
Arch Orthop Trauma Surg. 2012 Jan;132(1):25-31
21909815
Anesth Analg. 2008 Nov;107(5):1479-86
18931202
N Engl J Med. 1998 Jul 23;339(4):245-53
9673304
Spine (Phila Pa 1976). 2012 Oct 1;37(21):E1336-42
22772572
Spine (Phila Pa 1976). 2012 Apr 20;37(9):E549-55
22037532
Spine (Phila Pa 1976). 2008 Sep 15;33(20):2237-42
18794767
Spine (Phila Pa 1976). 2008 Nov 15;33(24):2577-80
19011538
PLoS One. 2013;8(2):e55436
23424632
Ann Thorac Surg. 2000 Apr;69(4):1298
10800856
Spine (Phila Pa 1976). 2014 Jul 15;39(16):1325-9
25010014
Spine (Phila Pa 1976). 2011 Nov 1;36(23):1913-8
21289587
Spine (Phila Pa 1976). 2008 Jan 1;33(1):108-13
18165756
Anesthesiology. 2005 Apr;102(4):727-32
15791100
N Engl J Med. 2007 May 31;356(22):2301-11
17538089
Br J Anaesth. 2013 Oct;111(4):549-63
23661406
Ann Thorac Surg. 1998 Mar;65(3):667-73
9527193
Neurosurg Focus. 2004 Jun 15;16(6):e1
15202871
Transfusion. 2011 Oct;51(10):2133-41
21575004
J Pediatr Orthop. 2003 Sep-Oct;23(5):661-4
12960633
Spine (Phila Pa 1976). 2004 Feb 1;29(3):233-8
14752343
Bone Joint J. 2014 Aug;96-B(8):1005-15
25086114
Spine (Phila Pa 1976). 2015 Apr 15;40(8):E443-9
25868100
Anesth Analg. 1999 Sep;89(3):590-7
10475286
J Thorac Cardiovasc Surg. 1996 Oct;112(4):1098-107
8873738
Pediatr Crit Care Med. 2009 Mar;10(2):182-90
19188875
Indian J Med Res. 2000 Feb;111:57-61
10824468
Anesth Analg. 2001 Jul;93(1):82-7
11429344
BMC Surg. 2010 Apr 06;10:13
20370916
Eur Spine J. 2013 Sep;22(9):2035-8
23715891
J Neurosurg Anesthesiol. 2011 Oct;23(4):290-6
21836528
Cochrane Database Syst Rev. 2011 Jan 19;(1):CD001886
21249650